05 March 2019
Construction of Nanoform’s GMP manufacturing plant rapidly progresses
Helsinki, Finland – Nanoform, an innovative drug enabling nanotechnology company, has announced significant progress in the construction of its new 600m2 GMP manufacturing plant, located at Cultivator II in Viikki Life Science Park, Finland. These important advancements in the project will enable the plant to begin operations in 2019.
Recent building progress includes the completed construction of the office space and R&D area in January, both of which are now operational. The project schedule has been accelerated with the commencement of work on the cleanroom and GMP-compliant areas, which are expected to be completed by the end of the third quarter. The facility is now on track to be licensed by the Finnish Medicines Agency by the end of this year.
By finalizing construction, Nanoform will double its capacity to handle potent APIs and provide nanonized materials for clinical trials. The rapid expansion in facilities will expediate further international commercialization of Nanoform’s nanonization™ technology, with patients across the globe set to benefit from the accelerated development of more efficient therapies.
Edward Hæggström, CEO of Nanoform, said: “We are delighted by the excellent construction progress that has already been achieved this year. The GMP manufacturing facility will allow more of our partners to benefit from our best-in-class nanoparticle engineering technology.”
Notes to the Editor
For further information, images and interview opportunities with Nanoform, please contact:
Pranika Sivakumar at Notch Communications
+44 (0) 161 457 7230
Nanoform Finland Limited is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to reduce clinical attrition and enhance their molecules formulation performance through its best-in-class nanonization™ services. The company’s multi-patented and scalable Controlled Expansion of Supercritical Solutions (CESSᵀᴹ) technology produces nanonized “designed-for-purpose” API particles, as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and improving their bioavailability. Nanoform’s unique nanonization™ technology provides novel opportunities in diverse value enhancing drug delivery applications.
For more information please visit www.nanoform.fi